Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs AZD 4547 (Primary)
- Indications Advanced breast cancer; Gastric cancer; Lung cancer; Oesophageal cancer
- Focus Biomarker; Pharmacodynamics; Proof of concept; Therapeutic Use
- Acronyms FGFR
- 10 Jun 2017 Biomarkers information updated
- 28 Nov 2015 Planned End Date changed from 31 Dec 2015 to 30 Apr 2017, according to United Kingdom Clinical Research Network record.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.